Replays 2024
| HEPATITIS B OPTIMAL MANAGEMENT |
||
| Long term efficacy and safety of NUCs: follow-up studies of TDF and TAF Maria BUTI (Spain) |
Replay | Presentation |
| Controversy: treat everyone with detectable HBV DNA? Yes ~ Jidong JIA (China) No ~ Thomas BERG (Germany) Discussion |
Replay | |
| STATE OF THE ART LECTURE Advances in the management of alcohol-related liver disease Aleksander KRAG (Denmark) |
Replay | |
| HEPATITIS DELTA OPTIMAL TREATMENT |
||
| Is chronic hepatitis delta more severe than chronic hepatitis B? Raymundo PARANA (Brazil) |
Replay | Presentation |
| PEG-IFN monotherapy Georgios PAPATHEODORIDIS (Greece) |
Replay | Presentation |
| Do NUCs improve the efficacy of Bulevirtide? Vasily ISAKOV (Russia) |
Replay | |
| Controversy: bulevirtide - Combine or not to PEG IFN? No ~ Pietro LAMPERTICO (Italy) Discussion |
Replay | |
| STATE OF THE ART LECTURE What’s new in auto-immune liver diseases? Michael MANNS (Germany) |
Replay | Presentation |
| HEPATITIS C: ARE WE ON TIME? |
||
| What actions to take to achieve HCV elimination? Robert GISH (USA) |
Replay | Presentation |
| Improving HCV-related morbidity and mortality Robert FLISIAK (Poland) |
Replay | Presentation |
| ADVANCES IN THE MANAGEMENT OF END-STAGE LIVER DISEASE | ||
| Encephalopathy revisited Dominique THABUT (France) |
Replay | Presentation |
| Sarcopenia, frailty in end-stage liver disease Claire FRANCOZ (France) |
Replay | Presentation |
| AWARD 2024 | ||
| Vascular liver diseases Dominique VALLA (France) |
Replay | |
| MASLD AND TYPE 2 DIABETES (T2D) | ||
| Pathophysiological relationship between MASLD and T2D Amalia GASTALDELLI (Italy) |
Replay | Presentation |
| NON-INVASIVE TESTS (NITS) IN MASLD IN 2024 | ||
| Limitations and challenges in the use of NITs Emmanouil TSOCHATZIS (UK) |
Replay | |
| Prognostic value of NITs Mazen NOUREDDIN (USA) |
Replay | Presentation |
| NITs use in clinical practice Jérôme BOURSIER (France) |
Replay | Presentation |
| TREATING MASH IN 2024 | ||
| Benefit of weight loss in MASH Raluca PAÏS (France) |
Replay | Presentation |
| Treatment response in MASH: are we ready for NITs? Arun SANYAL (USA) |
Replay | Presentation |
| HCC SESSION 1: DIAGNOSIS AND STAGING | ||
| Risk stratification-based surveillance of HCC Peter JEPSEN (Denmark) |
Replay | Presentation |
| Toward multiscale imaging of HCC Maxime RONOT (France) |
Replay | Presentation |
| STATE OF THE ART LECTURE Management of invasive procedures in patients with cirrhosis Pierre-Emmanuel RAUTOU (France) |
Replay | Presentation |
| HCC SESSION 2: MANAGEMENT | ||
| Interventional radiology Laura CROCETTI (Italy) |
Replay | Presentation |
| Towards manipulation of responses to immunotherapy in HCC Josep M. LLOVET (Spain) |
Replay | |
| Expanding liver transplantation options Norah TERRAULT (USA) |
Replay | Presentation |